ImmunityBio (NASDAQ:IBRX - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at D. Boral Capital in a research report issued on Monday,Benzinga reports. They presently have a $30.00 price objective on the stock.
A number of other equities research analysts have also issued reports on the company. BTIG Research started coverage on ImmunityBio in a research note on Friday, January 10th. They issued a "buy" rating and a $6.00 price target for the company. EF Hutton Acquisition Co. I raised ImmunityBio to a "strong-buy" rating in a research note on Wednesday, October 23rd.
Get Our Latest Research Report on IBRX
ImmunityBio Stock Down 1.3 %
NASDAQ:IBRX traded down $0.04 during trading hours on Monday, hitting $3.13. 7,526,509 shares of the stock traded hands, compared to its average volume of 6,623,175. The stock has a 50 day moving average price of $3.51 and a 200 day moving average price of $4.08. The company has a market cap of $2.18 billion, a price-to-earnings ratio of -3.40 and a beta of 0.86. ImmunityBio has a 1 year low of $2.28 and a 1 year high of $10.53.
Hedge Funds Weigh In On ImmunityBio
Institutional investors have recently added to or reduced their stakes in the company. State Street Corp boosted its position in shares of ImmunityBio by 10.1% during the 3rd quarter. State Street Corp now owns 8,654,460 shares of the company's stock valued at $32,195,000 after acquiring an additional 790,408 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in ImmunityBio by 2.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,265,981 shares of the company's stock valued at $4,709,000 after purchasing an additional 29,665 shares during the last quarter. Barclays PLC grew its stake in shares of ImmunityBio by 127.4% in the 3rd quarter. Barclays PLC now owns 361,036 shares of the company's stock worth $1,344,000 after buying an additional 202,248 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of ImmunityBio by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 147,754 shares of the company's stock worth $378,000 after buying an additional 13,788 shares during the last quarter. Finally, GSA Capital Partners LLP increased its holdings in shares of ImmunityBio by 290.3% in the 3rd quarter. GSA Capital Partners LLP now owns 107,985 shares of the company's stock worth $402,000 after buying an additional 80,318 shares during the last quarter. Hedge funds and other institutional investors own 8.58% of the company's stock.
About ImmunityBio
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Featured Articles
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
